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REGULATORY FRONTIERS
Integrating Social and Ethical Concerns
Into Regulatory Decision-Making for
Emerging Technologies
Gary Marchant, Ann Meyer & Megan Scanlon*
I. INTRODUCTION
Many emerging technologies—including advances in
genetic
medicine,
animal
and
plant
biotechnology,
nanotechnology, stem cells, robotics, synthetic biology, and
neuroscience—raise important ethical and social issues. These
issues are intensively debated in a variety of contexts by
stakeholders, scholars, and the researchers themselves during
the research stage of technology development. Discussion
appears in academic research projects and publications;
regional, national and international conferences; professional
associations; Congressional debates and reports; and
governmental advisory bodies such as the President’s Council
on Bioethics, the Secretary of Health and Human Services
(HHS) Advisory Committee on Genetics, Health and Society, or
the HHS Secretary’s Advisory Committee on Human Research
Protections. With a few relatively narrow exceptions for
requirements such as human subjects protection,1 however, the
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1. While Institutional Review Boards (IRBs) are required to review most
research involving human subjects, IRBs are expressly prohibited from
considering the longer-term ethical implications of proposed research. 45
C.F.R. § 46.111(a)(2) (2008) (“The IRB should not consider possible long-range
effects of applying knowledge gained in the research (for example, the possible
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impact of these debates on the direction and performance of
research is primarily hortatory and voluntary, with few
mandatory legal requirements or restrictions relating to ethical
and social concerns imposed at the research stage.
Ethical and social concerns may also animate market
forces in the form of consumer demands, as well as objections
once the technologies are commercialized. But between the
research and commercialization stages in the development of
emerging technologies, the regulatory-approval step provides
perhaps the best opportunity to expressly and formally consider
the ethical and social impacts of new technologies. Yet, when
confronted with making regulatory decisions that raise such
ethical and social concerns, federal regulatory agencies often
seem prevented by legal and practical restraints from
addressing those very issues.
This article considers the issue of whether and how
regulatory agencies should give more express consideration to
the ethical and social impacts of technologies they regulate.
Part II demonstrates that current practice and law generally
exclude the explicit and open consideration of ethical and social
issues. Part III sets forth the arguments for giving greater
weight to those issues in regulatory decision-making. Part IV
raises some potential concerns and pitfalls associated with
giving more express consideration to ethical and social
implications. Finally, Part V evaluates two potential models for
more explicitly incorporating ethical and social concerns into
regulatory decision-making.
II. EXCLUSION OF ETHICAL AND SOCIAL CONCERNS IN
CURRENT PRACTICE
While current U.S. regulatory regimes usually address
issues such as costs and impacts on health, safety, and the
environment, such regimes are generally structured to ignore
the social and ethical issues that arise in response to emerging
technologies. Yet, the concerns expressed by many members of
the public tend to be centered in the ethical and social realms,
whether presented as the “yuck” factor or repugnance in
response to technological developments that cause discomfort
or unease, or in more concrete and articulated moral or societal
effects of the research on public policy) as among those research risks that fall
within the purview of its responsibility.”).
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concerns.2 Examples of such concerns include the distributional
impacts of new technologies, their potential use for enhancing
humans, the “unnatural” nature of some of the interventions
made possible by new technologies, and the commoditization or
destruction of human or animal “life,” however defined.3
A recent example of a regulatory agency’s inability and
failure to address the public’s social and ethical concerns is the
decision by the Food and Drug Administration (FDA) to
approve the marketing of milk and meat from cloned animals.4
Thousands of members of the public took the time to prepare
and submit comments to the FDA raising social and ethical
concerns about the FDA’s proposed decision on cloned animals.5
While the substantive merits of these comments are certainly
debatable, the FDA refused to engage the issues altogether,
instead dismissing such claims with a cursory statement that
“the agency has not been charged with addressing moral,
religious, or ethical issues associated with animal cloning . . . .”6
Yet, a public opinion poll found that 63% of respondents felt
(53% felt strongly) that “[g]overnment regulators should

2. E.g., Kristen Kulinowski, Nanotechnology: From “Wow” to “Yuck”?, 24
BULL. SCI. TECH. & SOC’Y 13, 17 (2004); Leon R. Kass, Defending Human
Dignity, COMMENTARY, Dec. 2007, at 53, 54; Editorial, Beyond the Yuck
Factor, NEW SCIENTIST, June 25, 2005, at 5, 5.
3. See, e.g., Anne Chapman, Genetic Engineering: The Unnatural
Argument, 9 TECHNÉ 81, 8192 (2005) (arguing that genetic engineering is
unnatural and hence morally suspect); Kass, supra note 2, at 54 (discussing
nanomechanical implants that enhance sensation or motor skills and the
emerging science of producing man-machine hybrids).
4. See generally John F. Murphy, Mandatory Labeling of Food Made
From Cloned Animals: Grappling with Moral Objections to the Production of
Safe Products, 63 FOOD & DRUG L.J. 131 (2008) (recounting the origins of
cloned food, the FDA’s decision to approve products from cloned animals as
safe, and the legislative response to the FDA’s decision).
5. U.S. FOOD & DRUG ADMIN., FDA’S RESPONSE TO PUBLIC COMMENT ON
THE ANIMAL CLONING RISK ASSESSMENT, RISK MANAGEMENT PLAN, AND
GUIDANCE
FOR
INDUSTRY,
http://www.fda.gov/AnimalVeterinary/SafetyHealth/AnimalCloning/ucm05549
1.htm [hereinafter U.S. FOOD & DRUG ADMIN] (stating that the FDA received
approximately 30,500 comments); see also Rick Weiss, FDA is Set to Approve
Milk, Meat from Clones, WASH. POST, Oct. 17, 2006, at A1 (noting that surveys
showed that 60 percent of the U.S. population was uncomfortable with the
idea of cloning animals for milk and food); Zahra Meghani & Immaculada de
Melo-Martin, The U.S. Food and Drug Administration’s Evaluation of the
Safety of Animal Clones: A Failure to Recognize the Normativity of Risk
Assessment Projects, 29 BULL. OF SCI. TECH. & SOC’Y 9, 9 (2009) (questioning
the FDA’s stated mission and the adequacy of the public comment process).
6. U.S. FOOD & DRUG ADMIN., supra note 5, at 4.
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include ethical and moral considerations, in addition to
scientific evaluation of risks and benefits, when making
regulatory decisions about cloning or genetically modifying
animals.”7
The FDA’s refusal to consider such concerns is undoubtedly
correct in a legal sense. Congress charged the agency only with
ensuring that products are “safe” and “effective,”8 criteria that
do not seem to incorporate broader ethical or social concerns.
Nonetheless, it is problematic to dismiss as “out-of-bounds” the
deeply-felt views of many Americans who comment on a
proposed government action simply because their concerns are
outside the agency’s stated mission.
Many other examples of this problem exist. The approval of
drugs such as human growth hormone that have enhancement
as well as therapeutic applications proceeds without significant
consideration of the ethical concerns, and despite many
concerns among experts and the public about potential misuse
for enhancement purposes.9 As the number of available drugs
addressing cognitive performance (e.g., Alzheimer’s treatments)
is expected to expand over the next decade,10 the inability of
FDA to consider factors other than safety and efficacy will
become increasingly problematic and limiting. Similarly, much
of the opposition to genetically modified crops and foods is
based on ethical, social, and religious concerns,11 yet regulatory
agencies including the FDA, U.S. Department of Agriculture
(USDA), and Environmental Protection Agency (EPA) have not
given any explicit consideration or weight to such concerns.12

7. Memorandum from the Mellman Group to the Pew Initiative on Food
and
Biotechnology,
Recent
Findings,
at
7
(Nov.
7,
2005),
http://www.pewtrusts.org/uploadedFiles/wwwpewtrustsorg/News/Press_Releas
es/Food_and_Biotechnology/PIFB_Public_Sentiment_GM_Foods2005.pdf.
8. Federal Food, Drug, and Cosmetic Act, 21 U.S.C.A. § 393(b) (2009).
9. See, e.g., Dov Fox, Safety, Efficacy, and Authenticity: The Gap Between
Ethics and Law in FDA Decisionmaking, MICH. ST. L. REV. 1135, 1159-60
(2005).
10. See Robert E. Becker & Nigel H. Greig, Alzheimer’s Disease Drug
Development in 2008 and Beyond: Problems and Opportunities, 5 CURRENT
ALZHEIMER RES. 346, 346–47, 356 (2008).
11. Lynn Frewer et al., Societal Aspects of Genetically Modified Foods, 42
FOOD & CHEMICAL TOXICOLOGY 1181, 1183 (2004); Immaculada de MeloMartin & Zahra Meghani, Beyond Risk, 9 EMBO REP. 302, 302 (2008).
12. Melo-Martin & Meghani, supra note 11, at 305.
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III. THE CASE FOR INCLUSION OF SOCIAL AND
ETHICAL CONCERNS
As the ethical and social issues raised by new biomedical
and other emerging technologies continue to expand in the
future with growth in the capabilities and power of new
technologies, the current inability to consider ethical and social
issues in the context of regulatory decision-making will become
increasingly problematic. To be sure, there are other social
mechanisms including governmental ethics advisory bodies,
scholarly and public deliberations, and the new focus on
upstream engagement, available to address the social and
ethical impacts of new technologies.13 Notwithstanding such
forums and mechanisms, there remains a problem when ethical
or social issues are raised (often by the public) in specific
rulemaking proceedings, as agencies often lack the legal
jurisdiction or political wherewithal to respond on the merits.
Given that many of the public concerns about such technologies
are ethical or social in nature, it seems inappropriate from both
a normative and instrumental perspective for regulatory
agencies to continue to disregard such concerns because they
are outside of their stated regulatory missions.
The straightforward normative argument for regulatory
agency consideration of social concerns is that in a democratic
society, citizens should have the right to comment on whatever
issues concern them regarding government decisions. Moral
and social concerns are often deeply-felt and strongly-held by
many members of society, and in their perception such issues
cannot be divorced from the scientific, economic, and other
policy issues that regulatory agencies do consider.14 Thus, in a
democracy, citizens should have the right to raise moral and
social concerns about a proposed government action, and to
have those concerns considered and addressed by government
decision-makers.15
13. See JAMES WILSDON & REBECCA WILLIS, SEE-THROUGH SCIENCE:
WHY PUBLIC ENGAGEMENT NEEDS TO MOVE UPSTREAM (2004); Tee RogersHayden & Nick Pidgeon, Moving Engagement “Upstream”? Nanotechnologies
and the Royal Society and Royal Academy of Engineering’s Inquiry, 16 PUBLIC
UNDERSTANDING SCI. 345 (2007).
14. See Sheila Jasanoff, Technologies of Humility: Citizen Participation in
Governing Science, 41 MINERVA 223, 243 (2003) (arguing that public discussion
of science and technology should include ethical analysis).
15. See Marcy Darnovsky, Political Science, DEMOCRACY, Summer 2009,
at 36, 37, available at http://www.democracyjournal.org/pdf/13/Darnovsky.pdf
(last visited Jan. 23, 2010).
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There is also an instrumental value to agencies expressly
considering ethical and social concerns raised by the public.
The public is much more likely to accept a government decision
if its views have been accorded respect and consideration, even
when they do not agree with the ultimate decision
substantively, than if the government does not provide an
opportunity to air and consider those dissenting views.16 Thus,
regardless of the ultimate outcome of the decision-making
process, government decisions will be more credible if
regulators expressly consider the ethical and social issues that
concern members of the public.17
An additional instrumental argument is that ethical and
social issues are so central to decisions on many emerging
technologies that if they are not addressed explicitly, they will
inevitably be addressed implicitly or covertly. An example is
the recent FDA debacle over the Plan B emergency
contraceptive, where ethical and social concerns appeared to
motivate the agency’s reluctance to approve the product for
over-the-counter availability, yet the agency declined to be
explicit about these concerns and instead tried to camouflage
its decision on scientific and policy grounds that it perceived
were more legitimate.18 This ruse fooled no one–not the critics,
the media, Congress, or even scientists within the agency. The
FDA’s recalcitrance to approve the product was eventually
struck down by a federal court on the grounds of improper
decision-making criteria and procedure.19 The entire incident
left a blemish on the agency’s credibility and reputation.20
A final instrumental argument is that if the public’s ethical
and social concerns are not addressed now, those concerns will
fester and build up over time until they burst forth with
potentially devastating consequences for the scientific and
technological enterprise. As Leon Kass warned almost forty
years ago: “If attempts are not made early to detect and
diminish the social costs of biomedical advances by intelligent

16. NATIONAL RESEARCH COUNCIL, UNDERSTANDING RISK: INFORMING
DECISIONS IN A DEMOCRATIC SOCIETY 81–82 (Paul C. Stern & Harvey V.
Fineberg eds., 1996).
17. Frewer et al., supra note 11, at 1190.
18. See id. at 392–94.
19. Tummino v. Torti, 603 F. Supp. 2d 519, 547–48, 550 (E.D.N.Y. 2009).
20. See Frank Davidoff, Sex, Politics and Morality at the FDA: Reflections
on the Plan B Decision, HASTINGS CENTER REP., March 2006, at 20, 24–25.
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institutional regulation, the society is likely to react later with
more sweeping, immoderate, and throttling controls.”21 We may
already be experiencing the first waves of such pent-up public
frustrations as a result of past failures to adequately address
the public’s concerns. Those concerns, and the potentially
devastating long-term consequences of ignoring them, will
expand dramatically with the growing impact and
intrusiveness of emerging technologies.
In short, for both normative and instrumental reasons,
there is a strong presumptive case for allowing agencies to give
express consideration to ethical and social concerns in
regulatory decisions.
IV. CONCERNS ABOUT INCORPORATING ETHICAL AND
SOCIAL ISSUES
There are some reasons to be cautious about explicitly
incorporating ethical and social issues into regulatory decisionmaking. Unlike safety and efficacy, where people can fairly
easily reach consensus on what is a good or bad result (e.g.,
causing tumors is bad), there is more room for disagreement on
what is a good or bad moral or social effect.22 For example,
people may disagree on whether the alleged impact of genetic
engineering in promoting the consolidation of small family
farms into larger, more efficient industrial farms is a favorable
or unfavorable outcome.23 In the same vein, social and ethical
risks are more intangible, as well as harder to define and
quantify, and thus do not lend themselves to the same type of
quantitative analyses and validation that are common for
safety or efficacy determinations by regulatory agencies.24
21. Leon R. Kass, The New Biology: What Price Relieving Man’s Estate?,
174 SCI. 779, 787 (1971).
22. See Harold T. Shapiro, Reflections on the Interface of Bioethics, Public
Policy, and Science, 9 KENNEDY INST. ETHICS J. 209, 209 (1999) (“[W]e
continue to lack a moral consensus on some of the most profound ethical
claims that some believe ought to be more fully reflected in actual public
policies.”).
23. See, e.g., Daniel Lee Kleinman et al., Local Variation or Global
Convergence in Agricultural Biotechnology Policy? A Comparative Analysis, 36
SCI. & PUB. POL’Y 361, 365 (2009).
24. Such factors produce trepidation about the government wading into
ethical and moral issues. Thus, in one poll, approximately two-thirds of
respondents favored basing governmental regulatory decisions on scientific
factors alone, while only one-third favored decisions based on ethical and
social concerns. George Gaskell et al., Social Values and the Governance of
Science, 310 SCI. 1908, 1908 (2005). As the authors of this study note,
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Finally, ethical and social views are not fixed in time, but tend
to shift rapidly with changes in technological capabilities and
other societal factors.25
Other problems also justify caution in making regulatory
agencies the arbiters of moral correctness. The professional
staff of regulatory agencies consists primarily of scientists,
engineers, economists, and attorneys. Should these agencies be
staffed much more heavily with ethicists, social scientists, and,
perhaps, even theologians? Would we accept such a government
agency explicitly making moral and social decisions about
products such as the Plan B emergency contraceptive,
especially when the outcome might shift dramatically with a
change in administration?26 Given that ethical and moral
concerns are closely tied to religious beliefs for many people,
might allowing explicit moral and social decisions create a risk
of violating the First Amendment’s required separation of
church and state? Finally, regulatory agency officials have
expressed concern that requiring express consideration of
moral and ethical issues in regulatory actions would jeopardize
the perceived scientific basis and credibility of their decisions.27
Given the intangible and subjective nature of ethical and
social concerns, there is also a risk that government agencies
empowered to consider such concerns might publicly justify
regulatory decisions based on such factors, when protectionist
or other improper motives are the true rationale for the
decision.28 For example, several European Union (EU) member

however, alienating the significant minority who favor consideration of ethical
and social implications could adversely affect overall societal trust in new
technologies. Id. at 1909.
25. See Shapiro, supra note 22, at 210.
26. See Jonathan D. Rockoff, Critics Weigh in on FDA’s Decisions: Some
Say Ethics, Finances Should be Factors for Product Approval, BALTIMORE
SUN, Jan. 9, 2006 (quoting bioethicist Daniel Callahan opposing giving
agencies such as FDA authority to consider moral considerations in regulatory
decisions because “[a]ny solutions would, I think, reflect the position of the
party in power.”).
27. See id. (citing the argument of a former FDA official that “the agency’s
hard-won credibility would suffer if it abandoned its scientific focus”).
28. See LINDA NIELSEN & BERIT A. FABER, NAT’L CONSUMER AGENCY OF
DENMARK, ETHICAL PRINCIPLES IN EUROPEAN REGULATION OF
BIOTECHNOLOGY – POSSIBILITIES AND PITFALLS 22 (2002) (“Since ethical
concerns are difficult to document and might be perceived as a paving the way
for ulterior national interests . . . it is difficult to take account of these
concerns.”).
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states recently proposed that the EU regulatory approach to
GM foods should be revised to allow a member state to ban or
restrict genetically modified (GM) foods based on factors such
as social-economic and moral objections of the public.29 While
many EU citizens have genuine social and moral objections,
public opinion studies show that the primary concern is that
GM foods are unsafe.30 Yet, every major scientific organization
that has addressed the issue, including the EU’s own scientific
advisors, has concluded that GM foods are as safe, if not safer,
than conventional non-GM foods.31 Thus, ethical and social
concerns could act as a Trojan horse used to hide invalid or
inappropriate rationales that cannot stand up to public
scrutiny but which are nevertheless the true drivers of a
regulatory decision.
V. NEW APPROACHES FOR CONSIDERING ETHICAL
AND SOCIAL CONCERNS
The concerns described in the previous section suggest that
it might be problematic to give regulatory agencies direct and
express authority to make ethical or social judgments about
emerging technologies. On the other hand, it may be even more
objectionable to avoid these ethical and social considerations
altogether. Innovative new mechanisms or approaches are
needed to incorporate ethical and social concerns into
regulatory decisions on emerging technologies. Concurring in
this view, the Secretary’s Advisory Committee on Genetic

29. Memorandum from the General Secretariat, Council of Europe to the
Delegations,
Annex
(June
24,
2009),
available
at
http://register.consilium.europa.eu/pdf/en/09/st11/st11226-re02.en09.pdf (last
visited Jan. 23, 2010).
30. See, e.g., Montserrat Costa-Font et al., Consumer Acceptance,
Valuation of and Attitudes Towards Genetically Modified Food: Review and
Implications for Food Policy, 33 FOOD POL’Y 99, 107–108 (2008); Gunjan
Sinha, Up in Arms, 27 NATURE BIOTECHNOLOGY 592, 592–593 (2009).
31. See, e.g., European Commission, A Review of Results: EC-sponsored
Research
on
Safety
of
Genetically
Modified
Organisms,
http://ec.europa.eu/research/quality-of-life/gmo/index.html
(compiling
the
results of over 80 European Commission-sponsored research projects on the
safety of GM food); see also, e.g., NATIONAL RESEARCH COUNCIL,
ENVIRONMENTAL EFFECTS OF TRANSGENIC PLANTS 49 (2002) (“the transgenic
process presents no new categories of risk compared to conventional methods
of crop improvement”); NATIONAL RESEARCH COUNCIL, REPORT IN BRIEF:
SAFETY OF GENETICALLY ENGINEERED FOODS (2004) (“Genetic engineering . . .
poses no unique health risks that cannot also arise from conventional breeding
and other genetic alteration methods.”).
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Testing recommended in 2000 that:
In the future, [genetic] tests may be developed that raise major social
and ethical concerns. Because FDA’s review will focus on assuring the
analytical and clinical validity of a test, the agency’s capacity to
assess the ethical and social implications of a test may not be
sufficient. The Secretary should consider the development of a
mechanism to ensure the identification and appropriate review of
tests that raise major social and ethical concerns.32

Another group of experts likewise endorsed the creation of
mechanisms to explicitly consider the public’s social and ethical
concerns:
[I]t is becoming very apparent that institutional transparency,
coupled with the integration of public concerns into policy
development and implementation, will facilitate the introduction of
emerging technologies and their applications . . . into society. In order
that this strategy might be successful, it is important to understand
what is driving public concern, and to integrate this into policy
development rather than dismiss it as irrational as has sometimes
happened in the past.33

In designing mechanisms to better analyze and deliberate
on the moral and social dimensions of proposed regulatory
decisions, we must recognize that in the morally pluralistic
society in which live, consensus on these issues is highly
unlikely.34 Thus, the goal should not be to make any final
decision on these ethical and social issues, but to provide a
process whereby differing perspectives and interests can be
presented, discussed, and considered in a transparent and
explicit manner.
What might a new institutional approach look like? In the
remainder of this paper, we consider two possible models: (1)
the requirement for an ethical impact statement to accompany
regulations, and (2) the creation of an ethics review board to
review specific regulatory decisions. As analysis of real-world
examples will show, both models allow more explicit and formal
consideration of ethical and social issues in regulatory decision-

32. Public Comments on Preliminary Final Recommendations on
Oversight of Genetic Testing, 65 FED. REG. 21,094, 21,095 (July 2000); see also
Kass, supra note 21, at 787 (“Concepts of ‘risk’ and ‘cost’ need to be broadened
to include . . . social and ethical consequences.”).
33. Frewer et al., supra note 11, at 1191.
34. See Lonneke Poort, Consensus or Dissensus in the Legislative
Approach to Complex Policy Problems?: Animal Biotechnology as an Example
15 (Tilburg Working Paper Series on Jurisprudence and Legal History, No. 0803, 2008), available at http://ssrn.com/abstract=1284924.
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making.
A. ETHICAL IMPACT STATEMENT
A regulatory agency could be required to issue an “Ethical
Impact Statement” (“EthIS”) to accompany any significant
regulatory decisions. This EthIS would have to identify and
evaluate the ethical and social impacts of the agency’s proposed
decision and the efforts (if any) the agency was undertaking to
mitigate those impacts. This model is analogous to the
Environmental Impact Statement (EIS) that federal agencies
must issue under the National Environmental Policy Act
(“NEPA”) for any federal actions that will significantly affect
the human environment.35 Although NEPA does not have any
substantive impact in terms of limiting or directing an agency’s
decision,36 it does have a beneficial impact in forcing the agency
to be aware of the environmental impacts of its actions, and
informing the public of those impacts.37 An EthIS could operate
35. 42 U.S.C. § 4332 (2006). Various types of other impact statements are
required in other contexts, primarily in jurisdictions outside the United
States, which provide additional bodies of empirical evidence that could also
be used as models for an ethical impact statement. See, e.g., Roger Clarke,
Privacy Impact Assessment: Its Origins and Development, 25 COMPUTER L. &
SECURITY REV. 123, 123 (2009) (discussing privacy impact assessments); Janet
Collins & Jeffrey P. Koplan, Health Impact Assessment: A Step Toward Health
in All Policies, 302 JAMA315, 315 (2009). (discussing proposals for health
impact assessments “to examine the effects that a policy, program, or project
may have on the health of a population”); Elin Palm & Sven Ove Hansson, The
Case for Ethical Technology Assessment (eTA), 73 TECHNOLOGICAL
FORECASTING & SOC. CHANGE 543, 543–44 (2006) (proposing requirement for
an ethical technology assessment).
36. Marsh v. Ore. Natural Res. Council, 490 U.S. 360, 371 (1989) (“NEPA
does not work by mandating that agencies achieve particular substantive
environmental results.”).
37. See Inland Empire Pub. Lands Council v. U.S. Forest Serv., 88 F.3d
754, 758 (9th Cir. 1996) (“NEPA’s goal is satisfied once . . . information is
properly disclosed; thus, NEPA exists to ensure a process, not to ensure any
result.”); see also James M. McElfish, Jr., NEPA and Liberty, Now and
Forever, 39 ENVTL. L. REP. 10629, 10629 (2009) (“The result of these
procedures is that alternatives are considered that the government would not
have identified on its own, that data are discovered that the government
would not have otherwise identified, and that environmental issues are
studied that the government would not have identified or studied. Bad
decisions are sometimes avoided and good decisions made even better.
Mitigation measures are identified; some of them are even adopted.”). Despite
its many positive impacts, the NEPA EIS requirements has been criticized for
the amount of time and resources needed to complete an assessment, the low
quality of information and analysis often included, and the “ritualization” of
the process within agencies, stimulated by a desire to make litigation-proof
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in a similar manner with respect to a regulation’s ethical
implications.
Another precedent for an EthIS is the World Bank’s
requirement for a Poverty and Social Impact Analysis (“PSIA”).
The origins of the PSIA can be traced back to the 1995 World
Summit for Social Development in Copenhagen, which adopted
the Declaration on Social Development.38 As subsequently
articulated by the World Bank, the new approach to social
policy outlined by the Declaration involved a “political,
economic, ethical and spiritual vision [that is] based on human
dignity, human rights, equality, respect, peace, democracy,
mutual responsibility and cooperation, and full respect for the
various religions and ethical values and cultural backgrounds
of people.”39 This represented a significant broadening of the
Bank’s decision-making criteria beyond traditional economic
considerations. By the end of the 1990s, the World Bank had
revised its social development strategy to more explicitly
consider and give more weight to social norms, values, and
institutions, using “a holistic approach” that replaced the
Bank’s fixation on increasing income.40 One mechanism
adopted for implementing this strategy was a requirement to
conduct a PSIA of proposed policy reforms.41
A PSIA utilizes a multidisciplinary approach, integrating
both social and economic analytical tools, to perform an ex-ante
analysis of the social impacts of proposed policy reforms.42 A
decisions. See generally Bradley C. Karkkainen, Toward a Smarter NEPA:
Monitoring and Managing Government’s Environmental Performance, 102
COLUM. L. REV. 903, 91723 (2002).
38. See Antje Vetterlein, Economic Growth, Poverty Reduction, and the
Role of Social Policies: The Evolution of the World Bank’s Social Development
Approach, 13 GLOBAL GOVERNANCE 513, 527 (2007); see also SOC. DEV. DEP’T,
WORLD BANK, PAPER NO. 27, SOCIAL DEVELOPMENT UPDATE: MAKING
DEVELOPMENT MORE INCLUSIVE AND EFFECTIVE 1 (1998).
39. Vetterlein, supra note 38, at 527.
40. Id. at 518.
41. See id. at 528.
42. See INT’L BANK FOR RECONSTRUCTION & DEV., WORLD BANK, A USER’S
GUIDE TO POVERTY AND SOCIAL IMPACT ANALYSIS 1 (2003),
http://siteresources.worldbank.org/EXTTOPPSISOU/Resources/14240021185304794278/40260351185386760315/PSIA_English.pdf?resourceurlname=PSIA_English.pdf
[hereinafter PSIA USER’S GUIDE]. Although there is no fixed template for
analyzing the poverty and social impacts of policy, “it is possible to identify a
number of elements that make for good-practice PSIA.” Id. at 9. The ten
elements of a PSIA are: (1) asking the right questions, (2) identifying
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successful PSIA tends to have four characteristics: (1) it helps
to promote the use of a wider range of evidence in policy
making; (2) it “increases the extent to which distributional
equity is considered in the policy process by ensuring that
policies are not judged purely on aggregate economic efficiency
grounds,”; (3) it combines analysis with process to understand
and manage the political economy of reform, and (4) it
“supports inclusive policy making by providing evidence with
which policy makers and other stakeholders can inform their
discussions through existing or emerging policy processes.”43
An effective PSIA, thus, has two major impacts. First, it
informs policymakers about the likely societal implications of
different policy options to facilitate better and more sociallyconscious decision-making. Second, it informs and mobilizes
various constituencies in the affected jurisdiction with respect
to the probable social impacts of policy interventions, thereby
empowering such constituencies to engage with and influence
the policy-making process. For this to occur, it is important
that the information in the PSIA be collected and
communicated in a transparent manner, and opportunities be
afforded to stakeholders to participate in the policy-making
process.44
Identifying and engaging stakeholders early in the process
of a PSIA is essential to its success. The World Bank PSIA
procedure therefore calls for a “stakeholder analysis” to identify
“people, groups, and organizations that are important to take

stakeholders, (3) understanding transmission channels, (4) assessing
institutions, (5) gathering data and information, (6) analyzing impacts, (7)
contemplating enhancement and compensation measures, (8) assessing risks,
(9) monitoring and evaluating impacts, and (10) fostering policy debate and
feeding back into policy choice. Id.
43. JEREMY HOLLAND, TOOLS FOR INSTITUTIONAL, POLITICAL, AND SOCIAL
ANALYSIS OF POLICY REFORM 11 (2007).
44. INT’L BANK FOR RECONSTRUCTION & DEV., WORLD BANK, GOOD
PRACTICE NOTE: USING POVERTY AND SOCIAL IMPACT ANALYSIS TO SUPPORT
DEVELOPMENT
POLICY
OPERATIONS
17–20
(2008),
http://siteresources.worldbank.org/INTPSIA/Resources/GPN_August08_final.p
df [hereinafter GOOD PRACTICE NOTE]; see also PSIA USER’S GUIDE, supra
note 42, at 35. (“One way to approach this is to disseminate information about
the proposed reform and the results of the PSIA to the public, especially to key
stakeholders, and then to organize a policy forum where stakeholders can
discuss the tradeoffs involved. . . . Insights gained through dialogue may be
technical (for example, academic research) or social (for example, the
perspectives and concerns of groups that typically do not participate in the
formal policy debate process.”).
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into account.”45 The World Bank PSIA User’s Guide advises
splitting stakeholders into two primary groups, the first being
beneficiaries and those who suffer adverse impacts, and the
second consisting of organized groups such as unions, business
associations, donors, and civil society organizations.46 Once the
groups are identified, stakeholder analysis is used, going
beyond analyzing the interests of actors in relation to a policy
to requiring “key informant interviews” to evaluate interests,
and engaging appropriate stakeholders in the policy-making
process.47 The Bank also recognizes that the interests of
stakeholders who are less organized or lacking representation
may require the use of special surveys or focus groups.48 For
example, in Sri Lanka, a stakeholder analysis of the PSIA on
land reform showed that “groups likely to be affected by the
reform had not yet been consulted nor the impacts they would
face considered. By identifying these previously overlooked
stakeholder groups, the PSIA enabled their integration into a
facilitated consultation process around the reform proposal.”49
The PSIA requirements appear to have been successful in
promoting greater explicit consideration of social and ethical
impacts of World Bank decisions. For example, PSIA findings
regarding the social impacts of land and fertilizer reform in
Zambia sparked public debate among stakeholders.50
Eventually, PSIA disclosure and discussions led to broader
reforms in support of the land programs, including improved
road access, especially in remote areas, greater access to
fertilizer and functioning agricultural extension services.51 The
end result was that “[t]he PSIA seems to have had a major
impact on rethinking the need for and speed of a land reform of
the kind proposed by the government. Enough evidence was
produced through the PSIA analysis to lead policymakers to
45. PSIA USER’S GUIDE, supra note 42, at 10.
46. Id. at 11.
47. Id.
48. Id.
49. GOOD PRACTICE NOTE, supra note 44, at 15.
50. INT’L BANK FOR RECONSTRUCTION AND DEV., WORLD BANK, TOOLS
FOR INSTITUTIONAL, POLITICAL AND SOCIAL ANALYSIS OF POLICY REFORM: A
SOURCEBOOK FOR DEVELOPMENT PRACTITIONERS OR TIPS 38, 87–88 (2007),
http://web.worldbank.org/WBSITE/EXTERNAL/TOPICS/EXTSOCIALDEVEL
OPMENT/EXTTOPPSISOU/0,,menuPK:1424015~pagePK:64168427~piPK:641
68435~theSitePK:1424003,00.html (hereinafter TIPS SOURCEBOOK).
51. Id. at 89.
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rethink the necessity of such a comprehensive reform.”52
Both the EIS and PSIA examples demonstrate the
potential impact that a requirement for an analysis of
otherwise neglected or under-emphasized dimensions of a
decision can have in promoting greater awareness and
emphasis on those issues in decision-making. A requirement for
an agency to study and discuss the ethical and social impacts of
its regulatory decisions could bring greater scrutiny to such
issues. The EIS and PSIA examples demonstrate the need for
transparency, outreach, and public engagement to ensure full
ventilation of the ethical and social concerns of all sectors of
society in an EthIS.
Such an approach would also have its limitations. A
requirement to study and describe the ethical impacts would
not necessarily ensure that those factors are appropriately
incorporated into actual decisions. One major criticism of
NEPA is that it is only procedural and does not directly affect
the substance of regulatory decisions.53 Another issue in the
implementation of such a requirement would be the need for
some type of threshold and guidance criteria for when an EthIS
would be required and how much detail would be required.54
Many regulatory decisions may raise few, if any, ethical and
social issues, while other decisions may raise substantial
ethical and social concerns. A requirement for EthISs would
need a way to distinguish these situations through some sort of
threshold or tiered approach.
B. ETHICS REVIEW BOARD
A second potential model would be to create an ethics
review board (“ERB”) to evaluate and provide recommendations
regarding the ethical aspects of specific agency proposals. The
ERB could be situated within each agency, or could be
government-wide and centralized in the White House. Most
federal regulatory agencies already have similar advisory
committees to provide scientific advice; the proposed Ethics
52. Id.
53. See Matthew J. Lindstrom, Procedures Without Purpose: The
Withering Away of the National Environmental Policy Act’s Substantive Law,
20 J. LAND RESOURCES ENVTL L. 245 (2000).
54. For example, NEPA limits the application of the requirement to
prepare a full Environmental Impact Statement to only those government
actions “significantly affecting the quality of the human environment.” 42
U.S.C. § 4332(2)(C) (2000).
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Review Board would provide comparable advice on the ethical
and social dimensions of the agency’s actions. An ERB outside
of the agency might have greater independence and credibility
by being immune from any real or perceived control or
influence by the agency making the regulatory decision. It
would also promote consistency across federal agencies.
A centralized ERB would differ from existing structures
such as the President’s Council on Bioethics in that, instead of
considering ethical issues associated with biomedical
technologies in general,55 the ERB would review the ethical and
social dimensions of specific proposed regulatory actions by
agencies. One possible analogy to this review authority is the
Office of Management and Budget’s Office of Information and
Regulatory Affairs (OIRA), which conducts an independent
review of the economic analyses underlying proposed and final
substantial regulatory decisions by agencies.56
A precedent for a centralized ethical review body is
provided by the European Group on Ethics in Science and New
Technologies (EGE). This entity was originally constituted in
1991 as the Group of Advisers on the Ethical Implications of
Biotechnology (GAEIB), composed of six experts drawn from
law, science, medicine, philosophy, and theology.57 The group
and its responsibilities have continually expanded since its
creation.58 When the GAEIB’s mandate expired in 1997, the
European Commission replaced the group with the EGE.59 The
Commission enlarged the group to twelve members, and the
term for individual members was extended to from two to three
years.60 In 2005, it was further enlarged to fifteen members.61
EGE members are appointed by the E.U. Commission, and
include professors of philosophy, theology, medical and health
55. Exec. Order No. 13,237, 3 C.F.R. 821 (2001), reprinted in 5 U.S.C. § 14
app. 2 (2006).
56. Exec. Order No. 12,866, 58 FED. REG. 51,735 (1993); see also Office of
Management
and
Budget,
Information
and
Regulatory
Affairs,
http://www.whitehouse.gov/omb/regulatory_affairs/default/ (last visited Oct.
22, 2009).
57. Helen Busby et al., Ethical EU Law? The Influence of the European
Group on Ethics in Science and New Technologies, 33 EUR. L. REV. 803, 806
(2008).
58. Id. at 806–807.
59. Id. at 806.
60. Id.
61. Id.
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care ethics, genetics and public health, clinical pharmacology,
plant molecular genetics, food safety, information management,
and law who currently serve five-year terms.62 The EGE and its
predecessor, GAEIB, were created to address the perception
that the European Commission lacked the resources, expertise,
and authority to address the ethical implications of emerging
technologies such as biotechnology.63
There is no specific provision concerning ethics in the
Treaty of Europe, the convention creating the EU and its
various institutions and authorities.64 The EGE, therefore,
operates with little or no statutory or other legal authority or
requirements. The group creates its own rules for procedure.65
It has considerable autonomy; members provide their own
perspectives and judgments with no specific obligation to follow
or adhere to EU policies or interests.66
The EU Parliament and Council of Ministers may request
Opinions of the EGE, but the EGE can also initiate its own
opinions.67 The EGE is under a formal obligation to establish
close links with Commission departments involved in the issue
under consideration.68 The EGE has no other formal obligation
to consult other institutional actors, stakeholders, or the public,
although the EGE has established the practice of consulting
with outside experts to inform and support its opinions.69
Notwithstanding the perceived need for such a body to
provide expertise in ethics on emerging technologies, the EGE
has been subject to extensive debate regarding its legitimacy
and democratic accountability. Because technical experts who
make up the EGE and its various committees do not have any
political or social responsibilities to elected representatives or
EU citizens, their accountability is questionable.70 Despite
these ongoing questions about the legitimacy of the EGE, it
plays an influential role in EU law making and policy making.
It serves to validate EU-level legislation, provides an
interpretive reference point for policy, and serves as a forum for
62.
63.
64.
65.
66.
67.
68.
69.
70.

Id. at 806, 835–36.
See id. at 807–808.
See id. at 83738.
Id. at 839.
See id. at 838–39
See id. at 808, 839.
See id.
Id.
Id. at 805.
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airing ethical concerns raised by various civil society
constituencies.71 In all of these roles, the EGE must balance
economic growth and public acceptance.72 Increasingly the role
of the EGE is to mediate among the EU legislature and
executive, stakeholders such as industry seeking to enhance
the regulatory environment for the development of new
biotechnologies, and the citizenry who are suspicious of the
ethical adequacy of the regulatory environment.73 The courts,
including the European Court of Human Rights, have relied on
EGE opinions on such issues as ownership of unimplanted
embryos.74
The EGE is also influential in the adoption of EU
Directives. For example, Directive 98/4475 regarding legal
protection of biotechnological inventions was proposed in 1988,
but not passed for ten years because of controversial ethical
debates.76 The ethical principles outlined in EGE and GAEIB
opinions are reflected in the Directive, and it names the EGE
and acknowledges that their published opinions were taken
into account.77 Other EGE opinions identify ethical criteria that
should be considered in legislation, advocate for certain
positions, or set agendas for policy and legislation.78
EU directives not only reflect and endorse many EGE
recommendations, but occasionally also cite EGE opinions, and
state that additional opinions will be sought in the future.79
Commission press releases note that EGE opinions are taken
into consideration along with the EU Charter for Fundamental
Rights and documents of the Council of Europe, placing the
EGE on the same level as long-standing authoritative bodies.80
The EGE’s recommendations are not always accepted, however,
and some regulatory proposals may leave ethical concerns to

71. See id. at 805, 837–39.
72. Id. at 834.
73. Id. at 835.
74. Aurora Plomer, The European Group on Ethics: Law, Politics and the
Limits of Moral Integration in Europe, 14 EUR. L.J. 839, 839–40 (2008).
75. Council Directive 98/44, 1998 O.J. (L213) 13.
76. Busby, supra note 57, at 810.
77. Id. at 814.
78. See id. at 819.
79. See id. at 813–14.
80. Id. at 820.
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the individual EU member states.81
While the EGE has its limitations and controversies, it
does demonstrate that an ethics review board can be effective
in identifying, evaluating, and injecting into regulatory
decisions the ethical and social dimensions of emerging
technologies. The United States should consider adapting and
adopting a similar body for injecting ethical and social concerns
into regulatory decision-making.82
VI. CONCLUSION
Ethical and social issues are an inherent and unavoidable
aspect of many emerging technologies that will be entering the
regulatory pipeline over the next decade. Current regulatory
schemes are unable to adequately consider the ethical and
social concerns associated with such technologies. It is no
longer politically sustainable to ignore these ethical and social
concerns in regulatory decision-making, yet giving regulatory
agencies direct authority to evaluate and decide ethical issues
on their own is likely to over-extend their expertise and
legitimacy. Two alternative possible models to facilitate
attention to ethical and social issues are requiring an ethical
impact statement or creating an ethics advisory board to
identify, evaluate, and publicize the ethical and social
implications of proposed regulatory decisions. Both models
should be considered.

81. Id. at 821.
82. It should be noted that this model does not directly engage the public
to bring their social, ethical and religious concerns into the debate. Rather, the
ethics body (whether it is the EU’s, EGE, or the ERB proposed here) would
serve as a conduit for expressing such concerns in the regulatory context, even
though the relationship with the public would only be indirect.

